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Background-—Pulmonary embolism (PE) may trigger atrial ﬁbrillation through increased right atrial pressure and subsequent atrial
strain, but the degree of evidence is low. In this study, we wanted to investigate the impact of incident venous thromboembolism
(VTE) on future risk of atrial ﬁbrillation in a prospective population-based study.
Methods and Results-—The study included 29 974 subjects recruited from the Tromsø study (1994–1995, 2001–2002, 2007–
2008). Incident VTE and atrial ﬁbrillation events were registered from date of enrolment to end of follow-up, December 31, 2010.
Cox proportional hazard regression models using age as time-scale and VTE as a time-dependent variable were used to estimate
crude and multivariable hazard ratios (HRs) for atrial ﬁbrillation with 95% conﬁdence intervals (CIs). During 16 years of follow up,
540 (1.8%) subjects had an incident VTE event, and 1662 (5.54%) were diagnosed with atrial ﬁbrillation. Among those with VTE, 50
(9.3%) developed subsequent atrial ﬁbrillation. Patients with VTE had 63% higher risk of atrial ﬁbrillation compared to subjects
without VTE (multivariable-adjusted HR: 1.63, 95% CI: 1.22 to 2.17). The risk of atrial ﬁbrillation was particularly high during the
ﬁrst 6 months after the VTE event (HR 4.00, 95% CI: 2.21 to 7.25) and among those with PE (HR 1.78, 95% CI: 1.13 to 2.80).
Conclusions-—We found that incident VTE was associated with future risk of atrial ﬁbrillation. Our ﬁndings support the hypothesis
that PE may lead to cardiac dysfunctions that, in turn, could trigger atrial ﬁbrillation. ( J Am Heart Assoc. 2013;2:e000483 doi:
10.1161/JAHA.113.000483)
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A trial ﬁbrillation is the most common cardiac arrhythmiain the general population, with a lifetime risk of 1 in 4 for
persons over 40 years of age.1 It is associated with
substantial medical complications, such as a 5-fold increased
risk of ischemic stroke and doubled all-cause mortality.2
Although several risk factors for atrial ﬁbrillation (age, male
gender, hypertension, diabetes, thyroid disease, congestive
heart failure, sleep apnea, and renal failure)1,2 have been
identiﬁed, the major health burden posed by atrial ﬁbrillation
necessitates further investigation of predisposing conditions.
Atrial ﬁbrillation has been extensively studied in the context
of heart failure, hypertension, and acute myocardial infarc-
tion,3 but less attention has been paid to the relation between
venous thromboembolism (VTE) (pulmonary embolism and
deep vein thrombosis [DVT]) and atrial ﬁbrillation. The reported
prevalence of atrial ﬁbrillation in acute pulmonary embolism
(PE) varies widely,3–6 and most studies are focused on
diagnostic purposes.4,5 Moreover, as the temporal sequence
of events has not been determined in these studies,3,5,6 the
question of cause and effect remains unanswered.
The putative association between VTE and atrial ﬁbrillation is
strongly supported by convincing evidence for a pathophysio-
logical link between the diseases. An acute PE increases
pulmonary vascular resistance and cardiac afterload, eliciting
right ventricular and atrial strain that in turn may trigger atrial
ﬁbrillation.6,7 Even in normotensive patients, right ventricle
dysfunction occurs in50%of PE cases on admission,8 andmay
persist several months after the initial thrombotic event.9,10
Despite circumstantial evidence of an association, the
relationship between VTE and future atrial ﬁbrillation has
never been investigated in a prospective observational study.
In our study, we aimed to investigate whether VTE was
associated with risk of atrial ﬁbrillation in a cohort study with
subjects recruited from a general population.
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Methods
Study Population
Study participants were recruited from the fourth (1994–
1995), ﬁfth (2001–2002), and sixth survey (2007–2008) of
the Tromsø study. To these surveys, the entire population
(Tromsø 4) or parts (Tromsø 5 and 6) of the population aged
≥25 years living in the municipality of Tromsø, Norway, were
invited to participate. The overall attendance rate was high,
ranging from 77% in Tromsø 4 to 66% in Tromsø 6. A total of
30 586 subjects aged 25 to 97 years participated in at least
one of the surveys. A detailed description of study participa-
tion has been published elsewhere.11 The study was approved
by The Regional Committee of Medical and Health Research
Ethics North Norway, and all study participants provided
informed written consent. Subjects who did not consent to
medical research (n=225), those not ofﬁcially registered as
inhabitants of the municipality of Tromsø at time of enroll-
ment (n=47), and subjects with VTE (n=76) or atrial ﬁbrillation
(n=264) prior to baseline were excluded. In total, 29 974
subjects were included in the study (Figure 1), and followed
from the date of enrollment until the end of follow-up
(December 31, 2010).
Baseline Measurements
Baseline information was collected by physical examination,
nonfasting blood samples and self-administered question-
naires. Blood pressure was recorded with an automatic device
(Dinamap Vital Signs Monitor 1846; Critikon Inc) by trained
personnel. Participants rested for 2 minutes in a sitting
position and then 3 readings were taken on the upper right arm
at 2-minute intervals. The average of the 2 last readings was
used in the analysis. Nonfasting blood samples were collected
from an antecubital vein. Serum was prepared by centrifuga-
tion after a 1-hour respite at room temperature and analyzed at
the Department of Clinical Biochemistry, University Hospital of
North Norway. Serum total cholesterol was analyzed by an
enzymatic colorimetric method using a commercially available
kit (CHOD-PAP, Boehringer-Mannheim). Serum HDL-choles-
terol was measured after precipitation of lower-density
lipoproteins with heparin and manganese chloride. Body mass
index (BMI) was calculated as weight in kilograms divided by
the square of height in meters (kg/m2). History of arterial
cardiovascular disease (CVD) (angina pectoris, myocardial
infarction, or stroke), diabetes and current smoking was
obtained from a self-administered questionnaire.
Venous Thromboembolism: Identiﬁcation
and Validation
All incident VTE events during follow-up were identiﬁed by
searching the hospital discharge diagnosis registry, the
autopsy registry and the radiology procedure registry at the
University Hospital of North Norway as previously
described.12 All hospital care and relevant diagnostic radiol-
ogy in the Tromsø municipality are provided exclusively by this
hospital. The medical record for each potential VTE case was
reviewed by trained personnel. A potential VTE event derived
from the hospital discharge diagnosis registry or the radiology
procedure registry, was recorded when presence of clinical
signs and symptoms of DVT or PE were combined with
objective conﬁrmation tests (compression ultrasonography,
venography, spiral computed tomography, perfusion-ventila-
tion scan, pulmonary angiography, autopsy), and resulted in a
VTE diagnosis that required treatment. VTE cases from the
autopsy registry were recorded when the death certiﬁcate
indicated VTE as cause of death or a signiﬁcant condition
associated with death.
Atrial Fibrillation: Identiﬁcation and Validation
Incident events of atrial ﬁbrillation during follow-up were
identiﬁed by the hospital discharge diagnosis registry at the
University Hospital of North Norway (included diagnoses
from hospitalizations and outpatient clinic) and by the
National Causes of Death registry, using the following
International Classiﬁcation of Disease version 9 (ICD-9)
codes 427.0 to 427.99 and ICD-10 codes I47 to I48. In
addition, a search through medical records of patients with
cardiovascular disease (CVD) and cerebrovascular events
was performed.13 The diagnosis of atrial ﬁbrillation had to
be documented by an electrocardiogram, and adjudication
of the events was performed by an independent endpoint
committee. Classiﬁcation of atrial ﬁbrillation into paroxysmal
and persistent versus permanent forms was performed
when possible. Persons having a paroxysmal course of atrial
ﬁbrillation initially, but who later developed a permanent
form, were classiﬁed as having permanent atrial ﬁbrillation.
Coexisting heart disease at the time of atrial ﬁbrillation
diagnosis (coronary artery disease, congestive heart fail-
ure, valvular disease, structural changes) was recorded if
present.
Figure 1. Inclusion of study participants (unique individuals) from
the fourth, ﬁfth, and sixth survey of the Tromsø study.
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Statistical Analyses
Subjects who developed VTE during the study period
contributed with nonexposed person time from the baseline
inclusion date to the date of a diagnosis of VTE, and then
with exposed person time from the date of VTE and onwards.
Subjects diagnosed with incident atrial ﬁbrillation and VTE on
the same day (n=7) were excluded from the analyses
because the temporal sequence of events could not be
determined. For each participant, nonexposed and exposed
person-years were counted from the date of enrollment
(1994–1995, 2001–2002, or 2007–2008) to the date of an
incident atrial ﬁbrillation diagnosis, the date the participant
died or moved from the municipality of Tromsø, or until the
end of the study period, December 31, 2010, whichever
came ﬁrst. Subjects who died (n=3079) or moved from
Tromsø (n=4289) during follow-up were censored at the date
of migration or death.
Statistical analyses were performed with STATA version
12.0 (Stata Corporation). Cox proportional hazard regression
models were used to obtain crude and multivariable adjusted
hazard ratios (HR) with 95% conﬁdence intervals (CI). Attained
age was used as time-scale, with subjects’ age at study
enrollment deﬁned as entry-time, and exit-time deﬁned as age
at the censoring event (atrial ﬁbrillation, death, migration, or
study end). The exposure variable VTE was included as a time-
dependent variable using multiple observation periods per
subject. That is, no subjects were registered with VTE at
baseline, but the variable was updated for those who
developed VTE during follow-up. The multivariable HRs were
adjusted for potential confounders including sex, BMI, smok-
ing status, diastolic blood pressure, cholesterol levels, self-
reported CVD, and diabetes. In addition, subgroup analyses of
PE and DVT as exposure variables for atrial ﬁbrillation were
performed. Since the incidence of both VTE and atrial
ﬁbrillation highly increases with age, we also did age-stratiﬁed
analyses to explore the effect of VTE on atrial ﬁbrillation in
various age groups. A test of the proportional hazard
assumption using Schoenfeld residuals revealed that VTE
violated the assumption of proportional hazard. HRs in
different time intervals after the VTE event were therefore
calculated. Statistical interactions between VTE and sex or
age were tested by including cross-product terms in the
proportional hazard model. No statistical interactions
between VTE and sex or age were found. Correct assessment
of the temporal sequence of events was especially important
in this study because VTE can be both the cause and the
consequence of atrial ﬁbrillation, and patients can present
with the 2 conditions concomitantly. In the main analysis all
incident atrial ﬁbrillation events that occurred ≥1 day after
the diagnosis of VTE were considered as potentially caused by
the VTE. In addition, analyses excluding atrial ﬁbrillation
events occurring only in the presence of surgery or MI were
performed.
Results
Among 29 967 participants, 540 subjects were diagnosed
with VTE (crude IR: 1.48 [95% CI: 1.36 to 1.60] per 1000
person-years) and 1662 subjects were diagnosed with atrial
ﬁbrillation (crude IR 4.60 [95% CI: 4.39 to 4.83] per 1000
person-years) during a median of 15.7 years of follow-up.
There were 50 (9.3%) subjects who experienced subsequent
atrial ﬁbrillation after a VTE event, while 1612 (5.5%) were
diagnosed with atrial ﬁbrillation among subjects without VTE
during follow-up.
Table 1 presents the baseline characteristics for subjects
with VTE and subsequent atrial ﬁbrillation, those with VTE
only, those with atrial ﬁbrillation only, and for those with
neither VTE nor atrial ﬁbrillation during follow-up. Among
those with atrial ﬁbrillation only, 55.7% were men, while of
those with subsequent atrial ﬁbrillation after a diagnosis of
VTE only 42% were men. Those with atrial ﬁbrillation only and
those with VTE and subsequent atrial ﬁbrillation were on
average >20 years older than those with neither VTE nor atrial
ﬁbrillation. BMI, total cholesterol, and blood pressure were
highest among those with VTE and atrial ﬁbrillation, followed
by those with atrial ﬁbrillation only, those with VTE only, and
the lowest mean values were registered among those with no
events. Self-reported cardiovascular disease and diabetes
were most frequent among those with atrial ﬁbrillation with or
without a preceding event of VTE.
The characteristics of the incident atrial ﬁbrillation events
(n=1662) during follow-up are shown in Table 2. Coronary
artery disease was more prevalent in subjects who did not
experience a VTE event, while the percentages of subjects
with heart failure, valvular heart disease or structural heart
changes were similar between the 2 groups.
Incidence rates and hazard ratios for atrial ﬁbrillation in
subjects who developed VTE compared to subjects without
VTE during follow-up are presented in Table 3, and atrial
ﬁbrillation free survival curve for those with and without VTE
are shown in Figure 2. Subjects with VTE had a 1.8-fold
higher risk of atrial ﬁbrillation compared with those without
VTE. Similar risk estimates were found in multivariable
adjusted analyses (HR: 1.63, 95% CI: 1.22 to 2.17). Separate
analyses for PE and DVT showed that PE was associated
with higher relative and absolute risks for atrial ﬁbrillation
than DVT (Table 3). A PE event during follow-up was
associated with a 1.8-fold higher risk (HR: 1.78, 95% CI:
1.13 to 2.80), and a DVT event was associated with 1.5-fold
increased risk (HR: 1.51, 95% CI: 1.05 to 2.18) of atrial
ﬁbrillation compared to those without VTE during follow-up
(Table 3).
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Subjects with VTE and atrial ﬁbrillation were substantially
older than those without atrial ﬁbrillation. Therefore, we
additionally conducted age-stratiﬁed analyses to explore
whether the association was still present in various age
groups. In those younger than 65 years the HR of AF after a
VTE was 1.95 (95% CI: 0.81 to 4.73) compared to those
without a VTE, whereas in those above 65 years the HR was
1.83 (95% CI: 1.36 to 2.46). If the cut-off was set at age
75 years, the HR of AF after VTE was 1.88 (95% CI: 1.16 to
3.05) in those younger than 75, and 1.82 (95% CI: 1.28 to
2.58) in those older than 75 years (data not shown).
Figure 3 displays the age- and sex-adjusted hazard ratios for
atrial ﬁbrillation at different time intervals after a VTE diagnosis.
In the ﬁrst 6 months, VTE patients had a 4-fold higher risk of
atrial ﬁbrillation compared with subjects without VTE (HR: 4.00,
95% CI: 2.21 to 7.25). The hazard ratio declined steeply the ﬁrst
year after VTE diagnosis, but remained signiﬁcantly elevated in
the ﬁrst 3 years after the thrombotic event.
There were 239 cases of atrial ﬁbrillation that occurred
within 28 days after surgery or myocardial infarction. When
these cases were excluded, the risk of atrial ﬁbrillation in VTE
subjects was higher, with a HR of 1.80 (95% CI: 1.35 to 2.42)
in multivariable adjusted analyses (data not shown).
Discussion
In the present study, we found that patients with VTE had
increased risk of subsequent atrial ﬁbrillation. Overall,
subjects with VTE had a 1.6-fold higher risk of atrial ﬁbrillation
compared with those without VTE, and the risk was especially
high in the ﬁrst 6 months after the thromboembolic event. PE
was associated with higher relative and absolute risks for
atrial ﬁbrillation than DVT.
To the best of our knowledge, the present study is the ﬁrst
cohort study to show that VTE is associated with subsequent
Table 2. Characteristics of the Incident Atrial Fibrillation
Events (n=1662) During Follow-Up: The Tromsø Study
No VTE, % (n) VTE, % (n)
Atrial fibrillation 1612 50
Paroxystic/persistent* 40.5 (653) 50.0 (25)
Permanent 37.0 (596) 40.0 (20)
Post-operative AF† 9.8 (158) 2.0 (1)
Post-MI AF‡ 5.0 (80) —
Cardiac risk factors
Coronary artery disease§ 42.0 (677) 26.0 (13)
Heart failurek 16.1 (259) 16.0 (8)
Valvular heart disease 15.7 (253) 16.0 (8)
Structural heart changes 8.2 (132) 8.0 (4)
No known heart disease 34.6 (557) 48.0 (24)
AF indicates atrial ﬁbrillation; ICD, International Classiﬁcation of Disease; MI, myocardial
infarction.
*Atrial ﬁbrillation events were characterized as paroxystic/persistent or permanent
when possible.
†Within 28 days of surgery.
‡Within 28 days of an acute myocardial infarction.
§Previous myocardial infarction and/or atherosclerosis veriﬁed by coronary angiography.
kConsensus diagnosis based on information from medical journals, radiology reports,
echocardiographic ﬁndings, and ICD-10 codes.
Table 1. Baseline Characteristics of Subjects Without VTE With/Without Atrial Fibrillation During Follow-up and of Subjects With
VTE During Follow-up With/Without Subsequent Atrial Fibrillation During Follow-up
No VTE During Follow-up VTE During Follow-up
No Atrial Fibrillation Atrial Fibrillation No Atrial Fibrillation Subsequent Atrial Fibrillation
Subjects, n 27 815 1612 490 50
Sex (male), % 47.0 (13 065) 55.7 (898) 46.3 (227) 42.0 (21)
Age, y 45.214.0 64.011.7 56.814.2 68.39.4
BMI, kg/m2 25.23.9 26.94.3 26.74.4 29.24.0
Total cholesterol, mmol/L 5.931.29 6.681.24 6.561.35 6.941.18
HDL cholesterol, mmol/L 1.490.41 1.510.44 1.510.43 1.510.38
Systolic blood pressure, mm Hg 13220 15224 14122 15921
Diastolic blood pressure, mm Hg 7712 8614 8113 8813
Smoking, % 36.5 (10 121) 27.3 (439) 32.7 (160) 22.0 (11)
Self-reported CVD*, % 4.9 (1362) 23.4 (376) 11.0 (54) 22.0 (11)
Self-reported diabetes, % 1.6 (448) 5.3 (85) 2.5 (12) 6.0 (3)
Values are given as percentages with absolute numbers in brackets or as meansstandard deviations. BMI indicates body mass index; CVD, cardiovascular disease; HDL, high-density
lipoprotein; VTE, venous thromboembolism.
*Self-reported history of cardiovascular disease (angina pectoris, myocardial infarction, or stroke).
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risk of atrial ﬁbrillation in a general population. As this is an
observational study, we cannot draw any conclusions on the
pathophysiology behind this ﬁnding. However, the mechanistic
basis of such an association is supported in the literature. An
acute PE increases pulmonary vascular resistance and right
ventricular afterload by obstructing pulmonary arteries and
triggering the release of vasoconstrictive mediators.7 Conse-
quently, the increase in right ventricular and atrial pressures
elicits stretch injuries that, in turn, can trigger atrial ﬁbrilla-
tion.7,8 Atrial ﬁbrillation in acute PE patients likely reﬂects the
degree of right ventricular failure and hemodynamic compro-
mise.14 Even in hemodynamically stable patients, an acute PE
frequently presents with pulmonary hypertension and right
ventricular dysfunction.15,16 Right ventricular dysfunction was
also found to be an independent predictor of atrial ﬁbrillation in
patients with heart failure.17 The incidence of atrial ﬁbrillation
in patients with right ventricular dysfunction was 39% as
compared with 12% of patients with normal right ventricular
function.17
A feared complication of acute PE is development of
chronic thromboembolic pulmonary hypertension (CTEPH), in
which a mean pulmonary artery pressure >25 mm Hg persists
6 months after a PE diagnosis, resulting in chronic right
ventricular pressure overload.18 In a retrospective analysis of
231 patients with pulmonary hypertension including CTEPH
patients, the annual incidence of supraventricular tachycardia
(SVT) was 3%, with atrial ﬁbrillation and ﬂutter being the most
common types of SVT.19 Furthermore, although the majority of
PE survivors do not develop overt CTEPH, several studies show
long-term right ventricular abnormalities and functional limi-
tations in a signiﬁcant number of PE cases.9,10,20 In a study by
Kline and coworkers, elevated right ventricle systolic pressure
persisted 6 months after a PE in 50% of the patients, often
accompanied by dyspnea at rest or exercise intolerance.9 It is
Figure 2. Atrial ﬁbrillation free survival in subjects with and without
venous thromboembolism (VTE). The Tromsø study 1994-2010.
Figure 3. Age- and sex-adjusted hazard ratios with 95% conﬁdence
intervals for atrial ﬁbrillation at different time intervals after a
diagnosis of venous thromboembolism.
Table 3. Incidence Rates and Hazard Ratios for Atrial Fibrillation in Subjects Developing VTE, PE and DVT During Follow-up
Compared to Subject Without VTE During Follow-up
Person-Years AF Events Crude IR (95% CI) Model 1*, HR (95% CI) Model 2†, HR (95% CI)
Total VTE
No VTE 358 845 1612 4.5 (4.3 to 4.7) Ref Ref
VTE 2234 50 22.4 (17.0 to 29.5) 1.84 (1.39 to 2.44) 1.63 (1.22 to 2.17)
PE
No VTE 356 211 1612 4.5 (4.3 to 4.8) Ref Ref
PE 723 19 26.3 (16.8 to 41.2) 2.08 (1.32 to 3.28) 1.78 (1.13 to 2.80)
DVT
No VTE 356 950 1612 4.5 (4.3 to 4.7) Ref Ref
DVT 1511 31 20.5 (14.4 to 29.2) 1.69 (1.18 to 2.41) 1.51 (1.05 to 2.18)
AF indicates atrial ﬁbrillation; CI, conﬁdence interval; DVT, deep vein thrombosis; HR, hazard ratio; IR, incidence rate; PE, pulmonary embolism; VTE, venous thromboembolism.
*Using age as time scale.
†Using age as times.
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plausible that these morphological and functional changes
may result in atrial ﬁbrillation. Dilatation of the tricuspid valve
annulus and resultant tricuspid regurgitation is frequently seen
in patients with elevated pulmonary artery pressure. As the
right atrium dilates to accommodate the regurgitant volume,
ﬁbrosis may ensue, creating foci for reentry and thus, atrial
ﬁbrillation.7 We found atrial ﬁbrillation risk to be highest in the
ﬁrst 6 months after the thrombotic event, but it remained
elevated several years after VTE.
In our study, subjects with an isolated DVT had higher risk
of atrial ﬁbrillation compared to subjects without a VTE event.
As clinically silent PE is present in 30% of DVT cases,21
undiagnosed concurrent PE events may account for the higher
atrial ﬁbrillation risk observed among the DVT patients. Shared
environmental, genetic, or other risk factors for VTE and atrial
ﬁbrillation may also contribute to the observed association. In
a study by Poli and co-workers, the prevalence of the
prothrombin gene variant (G20210A), a known VTE risk factor,
was about 2-fold higher in atrial ﬁbrillation patients compared
with healthy controls.22 An Italian case report found subclinical
hyperthyroidism to both trigger paroxystic atrial ﬁbrillation and
induce a hypercoagulable state with resulting VTE.23
Major strengths of this study include the large number of
participants recruited from a general population, the high
attendance rate, the prospective design and the measure-
ments of potential confounders. We cannot exclude that
undetected atrial ﬁbrillation episodes prior to the recorded
VTE event may have biased our risk estimates. However, a
rigorous validation scheme of exposure and outcome vari-
ables was used to establish the temporal sequence of events
as accurately as possible. Some limitations merit consider-
ation. As many episodes of atrial ﬁbrillation are asymptom-
atic,24 an underestimation of the true incidence of atrial
ﬁbrillation in our study population is possible. Furthermore,
potential confounders such as BMI and co-morbidities were
assessed at baseline inclusion only, and these factors may
have changed over time.
In conclusion, patients with venous thromboembolism had
a higher risk of atrial ﬁbrillation, particularly during the ﬁrst
6 months after the incident VTE event. Our ﬁndings support
the concept that right ventricular pressure overload causes
persistent right-sided ventricular dysfunction and strain,
resulting in atrial stretch and subsequent ﬁbrillation.
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